摘要:
and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3a, R3b, R4, R5a, R5b, R6a, and R6b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions.
摘要:
Provided are methods of evaluating or treating a patient, e.g., a patient having a disorder described herein, comprising: a) optionally, acquiring a patient sample; b) acquiring an evaluation of and/or evaluating the sample for an alteration in the level S24(S)-hydroxycholesterol compared to a reference standard.
摘要:
The present invention relates to a process for the preparation of a compound of formula (I) said process comprising the steps of : a) reacting a compound of formula (II), with an acylating or a silylating agent to produce a compound of formula (III), wherein P 1 and P 2 are each independently a protecting group selected from R 2- Si-R 3 R 4 , or R 1 CO-, wherein R 1 is a group selected from C 1-6 alkyl or C 3-6 cycloalkyl, each group being optionally substituted by one or more substituents independently selected from fluoro or C 1-4 alkyl; R 2 , R 3 and R 4 are each independently a group selected from C 1-6 alkyl or phenyl, each group being optionally substituted by one or more substituents independently selected from fluoro or C 1-4 alkyl; b) reacting the compound of formula (III) in the presence of palladium acetate or a derivative thereof to produce compound of formula (IV); and c) reacting the compound of formula (IV) with a reducing agent to produce compound of formula (I).
摘要翻译:本发明涉及制备式(I)化合物的方法,所述方法包括以下步骤:a)使式(II)化合物与酰化剂或甲硅烷基化剂反应以制备式 III)表示的基团,其中P 1和P 2各自独立地选自R 2 -Si- R 3 R 4或R 1 CO-的保护基,其中R 1是选自C 1-6烷基或C 3-6环烷基的基团,各自 基团任选被一个或多个独立选自氟或C 1-4烷基的取代基取代; R 2,R 3和R 4各自独立地为选自C 1-6烷基或苯基的基团,每个基团任选被一个或多个独立地选自氟或C 1-4烷基的取代基取代; b)使式(III)化合物在乙酸钯或其衍生物存在下反应以产生式(IV)化合物; 和c)使式(IV)的化合物与还原剂反应以产生式(I)的化合物。
摘要:
The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-&kgr;B for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
摘要:
Provided herein are inhibitors of CYP11B, CYP17, and/or CYP21 enzymes of Formula Z, IX, X, XI, XII, XIII, XIV, XV, XVI, or XVII. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions.
摘要:
The present invention relates to a process for the preparation of estra-1,3,5(10)-trien-3,15α,16α,17β-tetraol (estetrol), via a silyl enol ether derivative 17-B-oxy-3-A-oxy-estra-1,3,5(10),16-tetraene, wherein A is a protecting group and B is ―Si(R 2 ) 3 . The invention further relates to a process for the synthesis of 3-A-oxy-estra-1,3,5(10),15-tetraen-17-one, wherein A is a protecting group, via said silyl enol ether derivative.
摘要:
Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6α and 7β oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6α and 7β oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and δ-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.
摘要:
16α,17α-Dialkylated steroids are prepared by reacting a 16α-alkyl-17(20)-enyl-20-silyl ether with an alkylating agent and an enol silyl ether cleaving agent in a suitable solvent.